Impact of Personalised Cardiac Anaesthesia and Cerebral Autoregulation on Neurological Outcomes in Patients Undergoing Cardiac Surgery
NCT05595954
Recruiting
This international, multicentre prospective cohort study will assess whether perioperative duration and magnitude of mean arterial pressure (MAP) outside of an individual's cerebral autoregulation (CA) limits using near-infrared spectroscopy (NIRS) and transcranial Doppler (TCD) are associated with adverse neurological events. It is to investigate whether patients with a higher burden of cerebral haemodynamic insults have an increased incidence or poorer neurological outcomes. Associations betwe... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/08/2024
Locations: Herzzentrum Dresden GmbH Universitätsklinik, Institut für Kardioanästhesiologie, Dresden, Not set +4 locations
Conditions: Postoperative Delirium, Postoperative Stroke, Postoperative Cognitive Dysfunction
Register for Updates
Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects
NCT06379958
Recruiting
A DDI study consisting of 4 parts conducted as an open label, fixed sequence study in healthy adult subjects.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/08/2024
Locations: Celerion, Belfast, Not set
Conditions: Pharmacokinetics
Register for Updates
Exploratory Study of Early Biomarkers Allowing Dynamic Assessment of Response to Treatment in Cancers of the Head and Neck
NCT05644457
Recruiting
DART is an exploratory molecular analysis study to assess potential early biomarkers of treatment response in squamous cell carcinoma of the head and neck (HNSCC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: The Royal Marsden Hospital, London, Not set
Conditions: Head and Neck Cancer
Register for Updates
Liquid Biopsy for Early DiagNosis of Squamous Cell Carcinoma of the HeAd and NeCk rEgion
NCT05645783
Recruiting
The 5-year survival for Head and Neck squamous cell carcinoma (HNSCC) across all TNM stage groups is approximately 50%. Patients who are present with stage I \& II disease have significantly better survival. When a patient presents to their general practitioner (GP) with symptoms suggestive of HNSCC, they may be referred for urgent specialist input through the suspected cancer referral (SCR) pathway, which include dedicated neck lump clinics. HNSCC is known to shed fragments of DNA, called circu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Kingston Hospital Foundation Trust, Kingston Upon Thames, Not set +1 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
ORganoid GeneratioN Study for Cancer
NCT05734963
Recruiting
ORIGINS - a multi-site sample collection study to establish patient-derived pre-clinical models for cancers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: The Royal Marsden Hospital, London, Not set
Conditions: Cancer
Register for Updates
Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer
NCT05837260
Recruiting
Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. This will eventually progress and at this point may become incurable with treatment options including complex and high risk surgery. The overall efficacy of systemic treatment in advanced thyroid cancer has a good initial response in most patients but not all. The study will collect tissues and blood samples for various protein analysis, nucleic acid extraction and live cell analysis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: The Royal Marsden NHS Foundation Trust, London, Not set
Conditions: Thyroid Cancer
Register for Updates
Sodium Accumulation Study in Haemodialysis: Brain Study
NCT05966116
Recruiting
The aim of the research study is to look at a new type of MRI scanning that can measure the amount of sodium in different parts of the body. Sodium (or 'salt') levels are very important in maintaining health, and high levels lead to high blood pressure. This is very important to patients with kidney disease, as the kidney is the main organ that regulates the amount of sodium in the body. It is possible to measure blood sodium levels, but this does not tell us how much sodium is present in other... Read More
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
08/07/2024
Locations: Centre for Kidney Research and Innovation, Derby, Not set
Conditions: Dialysis; Complications
Register for Updates
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
NCT05987176
Recruiting
An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver metastases. In this study, adjuvant treatment with 177Lu-DOTATATE will be compared with best supportive care in patients with well differentiated grade 1 or 2 neuroendocrine tumours in the stomach, pancreas or gut (gastro-entero-pancreatic NETs) who had their primary tumour alre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Imperial College Healthcare NHS Trust, London, Not set
Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Liver Metastases, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm
Register for Updates
The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy
NCT06097195
Recruiting
Neuronostics plan a prospective multisite trial to determine the clinical utility of BioEP in the context of diagnostic decision making. Neuronostics will use findings from the trial to improve user experience of the Neuronostics platform (the tool which clinicians use to obtain a BioEP score from EEG and the aligned report). The data coming from the trial will also enable Neuronostics to iterate the BioEP algorithms and so improve future performance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Royal Cornwall Hospitals Trust, Truro, Not set +1 locations
Conditions: Epilepsy
Register for Updates
ABTECT - Maintenance
NCT05535946
Recruiting
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhi... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/06/2024
Locations: University of Alabama -Birmingham, Birmingham, Alabama +553 locations
Conditions: Ulcerative Colitis
Register for Updates
Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects
NCT06511947
Recruiting
The primary objectives of this trial are to determine the pharmacokinetic (PK) profile and the safety and tolerability of GH001 delivered via a proprietary aerosol delivery device in healthy subjects after single-dose administration and a single-day individualized dosing regimen (IDR). As secondary objectives, the mebufotenin PK/ pharmacodynamic (PD) relationship, the PD profile of GH001 as evaluated by its psychoactive effects (PsE), the impact on cognitive performance, and the TCmax/2 and TCma... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/06/2024
Locations: GH Research Clinical Trial Site, London, Not set
Conditions: Healthy Volunteers
Register for Updates
Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)
NCT06545136
Recruiting
This is a multicenter, long-term, follow-up trial of participants with Gaucher disease type 1 who received FLT201 treatment in a preceding clinical trial. Participants will be followed for 5 years post-treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2024
Locations: Lysosomal Rare Disorders Research and Treatment Center, Fairfax, Virginia +3 locations
Conditions: Gaucher Disease, Type 1
Register for Updates